Kazumi Shiosaki

Kazumi is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. She is also a Board member of the Sandford Burnham Institute.

Previously, Kazumi was co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases. The company was acquired by Astellas Pharma in 2018.

Prior to Mitobridge, Kazumi was a co-founder and start-up CEO of Epizyme (NASDAQ:EPZM), a leader in novel epigenetic therapeutics for cancer. She has also been a Managing Director at MPM Capital. Kazumi started her career at AbbVie (then Abbott Labs) and from there joined Millennium (now part of Takeda), where she worked in senior functions in both research and corporate development.

Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley.